A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers

Summary

The purpose of this study is to determine the putative recommended phase 2 dose(s) (RP2Ds) and best way to take (optimal route of administration) JNJ-89402638 and to determine the safety of JNJ-89402638 at the RP2D(s) in participants with metastatic colorectal cancer (mCRC) and metastatic gastric cancer (mGAC) and to determine the safety and tolerability of JNJ-89402638 in combination with bevacizumab or biosimilar with or without chemotherapy in participants with mCRC.

Timeline

Start

2024-10-15

Primary completion

2028-02-25

Completion

2028-07-19

Drugs

Indications